Insmed to Present at the Stifel 2015 Healthcare Conference
11 Novembre 2015 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today reported that company management will participate at the
Stifel 2015 Healthcare Conference taking place in New York City on
November 18. Will Lewis, president and chief executive officer of
Insmed, will deliver a corporate overview at 3:00 PM ET.
Mr. Lewis’ presentation will be webcast live and can be accessed
by visiting the investor relations section of the company’s website
at www.insmed.com. The webcast will be archived for a period of 90
days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE™
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that can
lead to progressive inflammation and lung damage. There are
currently no products indicated for the treatment of NTM lung
disease in the United States or European Union (EU). In the EU, the
company has filed a marketing authorization application seeking
approval of ARIKAYCE for use in patients with NTM lung disease.
Insmed’s earlier-stage pipeline includes INS1009, a nebulized
prodrug formulation of treprostinil that the company is developing
for the treatment of pulmonary arterial hypertension (PAH), a
chronic, life-threatening disorder characterized by abnormally high
blood pressure in the arteries between the heart and lungs. To
complement its internal research, Insmed actively seeks
in-licensing opportunities for a broad range of rare
diseases. For more information, visit www.insmed.com.
“Insmed” and “ARIKAYCE” are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
susan.mesco@insmed.com
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024